Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pidotimod adjuvant treatment for children with recurrent respiratory tract infection
ChiCTR2000038335Phase 4Completed
- Sponsor
- Shengjing Hospital of China Medical University
- Start
- Jun 2018
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of pidotimod in Airways Infection (2 arms), sponsored by Shengjing Hospital of China Medical University. Primary endpoint: Change in the number of respiratory tract infections within 180 days after the end of treatment. Started Jun 2018; status: completed.
02
Drugs
pidotimod
03
Conditions
Airways Infection
Beyond the preview
Go deeper on ChiCTR2000038335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000038335.